- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- March 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- January 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- February 2025
- 199 Pages
Global
From €3979EUR$4,500USD£3,432GBP
- Report
- October 2024
- 200 Pages
Global
From €3316EUR$3,750USD£2,860GBP
- Report
- May 2025
- 230 Pages
United States
From €2476EUR$2,800USD£2,136GBP
€3537EUR$4,000USD£3,051GBP
- Report
- March 2024
- 239 Pages
Global
From €5219EUR$6,109USD£4,350GBP
- Report
- May 2023
- 163 Pages
Global
From €5261EUR$5,950USD£4,538GBP
- Report
- January 2021
- 201 Pages
Global
From €3183EUR$3,600USD£2,746GBP
Trumenba is a vaccine developed by Pfizer and BioNTech for the prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. It is approved for use in individuals aged 10 through 25 years in the United States. The vaccine is administered in two doses, with the second dose given 6 months after the first.
Trumenba is part of a growing market of vaccines designed to protect against meningococcal disease. Other vaccines in this market include Menactra, Menveo, and Bexsero. These vaccines are used to protect against different serogroups of Neisseria meningitidis, and are approved for use in different age groups.
The companies in the Trumenba market include Pfizer and BioNTech, Sanofi Pasteur, GlaxoSmithKline, and Novartis. Show Less Read more
